|
|
 Previous Article | Table of Contents | Next Article 
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's
disease
K Yoshizaki, T Matsuda, N Nishimoto, T Kuritani, L Taeho, K Aozasa, T Nakahata, H Kawai, H Tagoh and T Komori
Department of Medicine, Osaka University Medical School, Japan.
Castleman's disease is a syndrome consisting of giant lymph node
hyperplasia with plasma cell infiltration, fever, anemia,
hypergammaglobulinemia, and an increase in the plasma level of acute phase
proteins. It has been reported that clinical abnormalities disappear after
the resection of the affected lymph nodes, suggesting that products of
lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is
a cytokine inducing B-cell differentiation to immunoglobulin-producing
cells and regulating biosynthesis of acute phase proteins. This report
demonstrates that the germinal centers of hyperplastic lymph nodes of
patients with Castleman's disease produce large quantities of IL-6 without
any significant production of other cytokines. In a patient with a solitary
hyperplastic lymph node, clinical improvement and decrease in serum IL-6
were observed following surgical removal of the involved lymph node. There
was a correlation between serum IL-6 level, lymph node hyperplasia,
hypergammaglobulinemia, increased level of acute phase proteins, and
clinical abnormalities. The findings in this report indicate that the
generation of IL-6 by B cells in germinal centers of hyperplastic lymph
nodes of Castleman's disease may be the key element responsible for the
variety of clinical symptoms in this disease.
Volume 74,
Issue 4,
pp. 1360-1367,
09/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Kurosawa, N. Akiyama, A. Ohwada, M. Warabi, M. Suenaga, M. Kojima, and J. Tomiyama
Idiopathic Plasmacytic Lymphadenopathy with Polyclonal Hypergammaglobulinemia Accompanied with Cutaneous Involvement and Renal Dysfunction
Jpn. J. Clin. Oncol.,
October 1, 2009;
39(10):
682 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Morishima, A. Marui, T. Shimamoto, Y. Saji, T. Nishina, and M. Komeda
A case of interleukin-6-producing cardiac myxoma resembling multicentric Castleman's disease.
J. Thorac. Cardiovasc. Surg.,
August 1, 2009;
138(2):
499 - 501.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamamoto, H. Takahashi, K. Hasebe, C. Suzuki, Y. Naishiro, T. Hayashi, H. Yamamoto, T. Ishida, and Y. Shinomura
The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome--expansion of SIPS to the territory of Castleman's disease
Rheumatology,
July 1, 2009;
48(7):
860 - 862.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chen, G. Sandford, and J. Nicholas
Intracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6
J. Virol.,
January 15, 2009;
83(2):
722 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, and T. Kakehi
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Blood,
November 15, 2008;
112(10):
3959 - 3964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kojima, N. Nakamura, N. Tsukamoto, Y. Otuski, K. Shimizu, H. Itoh, S. Kobayashi, H. Kobayashi, T. Murase, N. Masawa, et al.
Clinical Implications of Idiopathic Multicentric Castleman Disease Among Japanese: A Report of 28 Cases
International Journal of Surgical Pathology,
October 1, 2008;
16(4):
391 - 398.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Kojima, S. Miyawaki, S. Takada, K. Kashiwabara, T. Igarashi, and S. Nakamura
Lymphoplasmacytic Infiltrate of Regional Lymph Nodes in Kuttner's Tumor (Chronic Sclerosing Sialadenitis): A Report of 3 Cases
International Journal of Surgical Pathology,
July 1, 2008;
16(3):
263 - 268.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B C Gleason and J L Hornick
Inflammatory myofibroblastic tumours: where are we now?
J. Clin. Pathol.,
April 1, 2008;
61(4):
428 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Zhang, R. S. Bonaparte, D. Patel, D. A. Stein, and P. L. Iversen
Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus
Mol. Cancer Ther.,
March 1, 2008;
7(3):
712 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kawabata, N. Tomosugi, J. Kanda, Y. Tanaka, K. Yoshizaki, and T. Uchiyama
Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease
Haematologica,
June 1, 2007;
92(6):
857 - 858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Brinkmann, M. Pietrek, O. Dittrich-Breiholz, M. Kracht, and T. F. Schulz
Modulation of Host Gene Expression by the K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus
J. Virol.,
January 1, 2007;
81(1):
42 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Peters, W. Bloch, C. Wickenhauser, S. Tawadros, T. Oreshkova, D. Kess, T. Krieg, W. Muller, and K. Scharffetter-Kochanek
Terminal B cell differentiation is skewed by deregulated interleukin-6 secretion in {beta}2 integrin-deficient mice
J. Leukoc. Biol.,
September 1, 2006;
80(3):
599 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tabata, H. Kubo, R. Tabata, M. Wada, K. Sakuma, M. Ichikawa, S. Fujita, T. Mio, and M. Mishima
All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system
Am J Physiol Lung Cell Mol Physiol,
March 1, 2006;
290(3):
L597 - L606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, L. Achouh, A. G. Marcelin, J-P. Viard, O. Hermine, D. Canioni, O. Sitbon, G. Simonneau, and M. Humbert
Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
Eur. Respir. J.,
November 1, 2005;
26(5):
969 - 972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, Y. Kanakura, K. Aozasa, T. Johkoh, M. Nakamura, S. Nakano, N. Nakano, Y. Ikeda, T. Sasaki, K. Nishioka, et al.
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
Blood,
October 15, 2005;
106(8):
2627 - 2632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dagna, F. Broccolo, C. T. Paties, M. Ferrarini, L. Sarmati, L. Praderio, M. G. Sabbadini, P. Lusso, and M. S. Malnati
A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection
N. Engl. J. Med.,
July 14, 2005;
353(2):
156 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Dawson and A. M. Aspitia
44-Year-Old Man With Fatigue and Anemia
Mayo Clin. Proc.,
June 1, 2004;
79(6):
817 - 820.
[PDF]
|
|
|
|
|
|
|
C. P. Jung, S. Horster, P. Lohse, J. R. Bogner, B. Emmerich, and F. D. Goebel
Uncommon Hematologic Malignancies: CASE 1. PLASMABLASTIC LEUKEMIA IN HIV-ASSOCIATED MULTICENTRIC CASTLEMAN'S DISEASE
J. Clin. Oncol.,
November 15, 2003;
21(22):
4248 - 4249.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-F. Ko, S.-H. Ng, M.-J. Hsieh, J.-W. Lin, C.-C. Huang, T.-Y. Lee, and W.-J. Chen
Castleman disease of the pleura: experience with eight surgically proven cases
Ann. Thorac. Surg.,
July 1, 2003;
76(1):
219 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hayashi, M.-C. Rho, A. Enomoto, A. Fukami, Y.-P. Kim, Y. Kikuchi, T. Sunazuka, T. Hirose, K. Komiyama, and S. Omura
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
PNAS,
November 12, 2002;
99(23):
14728 - 14733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hayashi, M.-C. Rho, A. Fukami, A. Enomoto, S. Nonaka, Y. Sekiguchi, T. Yanagisawa, A. Yamashita, T. Nogawa, Y. Kamano, et al.
Biological Activity of a Novel Nonpeptide Antagonist to the Interleukin-6 Receptor 20S,21-Epoxy-resibufogenin-3-formate
J. Pharmacol. Exp. Ther.,
October 1, 2002;
303(1):
104 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Polson, D. Wang, J. DeRisi, and D. Ganem
Modulation of Host Gene Expression by the Constitutively Active G Protein-coupled Receptor of Kaposi's Sarcoma-associated Herpesvirus
Cancer Res.,
August 1, 2002;
62(15):
4525 - 4530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Li and J. Nicholas
Identification of Amino Acid Residues of gp130 Signal Transducer and gp80 {alpha} Receptor Subunit That Are Involved in Ligand Binding and Signaling by Human Herpesvirus 8-Encoded Interleukin-6
J. Virol.,
May 3, 2002;
76(11):
5627 - 5636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Oksenhendler, E. Boulanger, L. Galicier, M.-Q. Du, N. Dupin, T. C. Diss, R. Hamoudi, M.-T. Daniel, F. Agbalika, C. Boshoff, et al.
High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease
Blood,
April 1, 2002;
99(7):
2331 - 2336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. De Benedetti, P. Pignatti, M. Vivarelli, C. Meazza, G. Ciliberto, R. Savino, and A. Martini
In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist
J. Immunol.,
April 1, 2001;
166(7):
4334 - 4340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-Q. Du, H. Liu, T. C. Diss, H. Ye, R. A. Hamoudi, N. Dupin, V. Meignin, E. Oksenhendler, C. Boshoff, and P. G. Isaacson
Kaposi sarcoma-associated herpesvirus infects monotypic (IgM{lambda}) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders
Blood,
April 1, 2001;
97(7):
2130 - 2136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, T. Kishimoto, and K. Yoshizaki
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Ann Rheum Dis,
November 1, 2000;
59(90001):
i21 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Oksenhendler, G. Carcelain, Y. Aoki, E. Boulanger, A. Maillard, J.-P. Clauvel, and F. Agbalika
High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients
Blood,
September 15, 2000;
96(6):
2069 - 2073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Menke;, P. G. Isaacson, and C. Boshoff
Ly-1b cells and Castleman disease
Blood,
August 15, 2000;
96(4):
1614 - 1616.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-G. Judde, V. Lacoste, J. Briere, E. Kassa-Kelembho, E. Clyti, P. Couppie, C. Buchrieser, M. Tulliez, J. Morvan, and A. Gessain
Monoclonality or Oligoclonality of Human Herpesvirus 8 Terminal Repeat Sequences in Kaposi's Sarcoma and Other Diseases
J Natl Cancer Inst,
May 3, 2000;
92(9):
729 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, T. Kishimoto, and K. Yoshizaki
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Blood,
January 1, 2000;
95(1):
56 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Wong, E. P. Bergquam, R. M. Swanson, F. W. Lee, S. M. Shiigi, N. A. Avery, J. W. Fanton, and M. K. Axthelm
Induction of B Cell Hyperplasia in Simian Immunodeficiency Virus-Infected Rhesus Macaques with the Simian Homologue of Kaposi's Sarcoma-Associated Herpesvirus
J. Exp. Med.,
September 20, 1999;
190(6):
827 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aoki, E. S. Jaffe, Y. Chang, K. Jones, J. Teruya-Feldstein, P. S. Moore, and G. Tosato
Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6
Blood,
June 15, 1999;
93(12):
4034 - 4043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Belec, A. S. Mohamed, F.-J. Authier, M.-C. Hallouin, A. M. Soe, S. Cotigny, P. Gaulard, and R. K. Gherardi
Human Herpesvirus 8 Infection in Patients With POEMS Syndrome-Associated Multicentric Castleman's Disease
Blood,
June 1, 1999;
93(11):
3643 - 3653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Staskus, R. Sun, G. Miller, P. Racz, A. Jaslowski, C. Metroka, H. Brett-Smith, and A. T. Haase
Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi's Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman's Disease
J. Virol.,
May 1, 1999;
73(5):
4181 - 4187.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Muller-Newen, A. Kuster, U. Hemmann, R. Keul, U. Horsten, A. Martens, L. Graeve, J. Wijdenes, and P. C. Heinrich
Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses
J. Immunol.,
December 1, 1998;
161(11):
6347 - 6355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Okada and S. Murakami
Cytokine Expression in Periodontal Health and Disease
Critical Reviews in Oral Biology & Medicine,
January 1, 1998;
9(3):
248 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J D Pollard and G A R Young
Neurology and the bone marrow
J. Neurol. Neurosurg. Psychiatry,
December 1, 1997;
63(6):
706 - 717.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Boshoff, Y. Endo, P. D. Collins, Y. Takeuchi, J. D. Reeves, V. L. Schweickart, M. A. Siani, T. Sasaki, T. J. Williams, P. W. Gray, et al.
Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines
Science,
October 10, 1997;
278(5336):
290 - 294.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. T. Beck, S.-M. Hsu, J. Wijdenes, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, and B. Barlogie
Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody
N. Engl. J. Med.,
March 3, 1994;
330(9):
602 - 605.
[Full Text]
|
|
|
|
|
|
|
C. E. Dunbar and A. W. Nienhuis
Multiple Myeloma: New Approaches to Therapy
JAMA,
May 12, 1993;
269(18):
2412 - 2416.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. O. Williams, P. M. Banks, A. G. Liebelt, H. L. Stewart, and U. Saffiotti
Angiofollicular Lymphoid Hyperplasia (Castleman's Disease) in Two Mice Treated with Polyoma Virus or Urethane
Toxicol Pathol,
January 1, 1993;
21(1):
26 - 34.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Nakahama, M. Okada, M. Miyazaki, N. Imai, T. Yokokawa, and S. Kubori
Distinct Responses of Interleukin-6 and Other Laboratory Parameters to Treatment in a Patient with Polyarteritis Nodosa A Case Report
Angiology,
June 1, 1992;
43(6):
512 - 516.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. F. Terry, V. Loukaci, and F. R. Green
Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation
J. Biol. Chem.,
June 9, 2000;
275(24):
18138 - 18144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
